Alector, Inc. — FY2020 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2020. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies for neurodegenerative diseases. It had no approved products and no product-sales revenue; reported revenue primarily reflects its collaboration with AbbVie.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $21.1 million | $21.2 million |
| Research and development expense | $156.9 million | $100.5 million |
| General and administrative expense | $59.4 million | $35.1 million |
| Operating loss | $195.2 million | $114.4 million |
| Net loss | $190.2 million | $105.4 million |
| Net loss per share, basic and diluted | $2.45 | $1.71 |
| Cash used in operating activities | $166.7 million | $99.3 million |
At year-end, cash and cash equivalents were $50.0 million and marketable securities were $363.3 million, totaling $413.3 million. Current assets were $421.5 million and current liabilities $68.1 million. Total liabilities were $220.7 million, including $51.3 million of operating lease liabilities; the filing does not identify outstanding borrowings or financial debt. Deferred revenue was $132.3 million. The company reported an accumulated deficit of $410.0 million.
The January 2020 follow-on offering generated $224.5 million in net proceeds. Cash provided by financing activities was $232.1 million. The filing gives inconsistent runway statements: one section says existing resources were expected to fund operations through at least mid-2022, while another says through at least 12 months after filing. These are management estimates, not guarantees.
Material changes versus the prior year
- Net loss increased by $84.8 million, while operating expenses rose $80.6 million; revenue was essentially flat.
- R&D expense rose $56.3 million, reflecting higher AL001 manufacturing and clinical costs, increased personnel expense, investment in AL044, and other early-stage programs.
- G&A expense increased $24.3 million, mainly from higher personnel and legal expenses, including the co-founder arbitration.
- Operating cash use increased by $67.4 million. A $30.5 million noncash stock-based compensation charge partially offset cash use.
Pipeline, outlook, risks and unusual items
- AL001: Entered the global pivotal Phase 3 INFRONT-3 trial in July 2020 for symptomatic and presymptomatic FTD-GRN. Earlier studies showed target engagement and increases in PGRN; management reported generally favorable safety and tolerability findings to date. The Phase 3 trial planned to enroll up to 180 participants.
- AL101: Phase 1a began in January 2020; management expected initial data in 2021. It is intended for broader neurodegenerative indications, including Alzheimer’s and Parkinson’s disease.
- AL002 and AL003: Both are being developed with AbbVie. Alector closed enrollment in AL002’s Phase 1b Alzheimer’s study, which was affected by COVID-19; a Phase 2 trial began in January 2021. AL003’s Phase 1b study was progressing, with data expected in 2021.
- Additional programs and collaboration: AL044 targets MS4A4A and was in development. Innovent licensed AL008 rights in China; no revenue or payments under that agreement had been recognized by year-end. AbbVie’s options and potential milestone payments are contingent on future development and other conditions.
- Outlook: Management expected higher R&D and operating costs as clinical programs advanced and stated that additional financing would be needed over time. No specific revenue or earnings guidance was provided. The company had no marketed products and anticipated no product-sales revenue in the near term.
- COVID-19: The filing describes trial-site delays, missed or delayed participant doses, recruitment and operational risks, and possible effects on trial data and timelines.
- Unusual item / contingency: An arbitrator found former consulting co-founder Asa Abeliovich liable for breach of confidentiality and document spoliation and awarded damages and sanctions; the monetary amount remained to be determined in a pending proceeding.
- Financial reporting: The auditor issued an unqualified opinion on the financial statements and internal controls. Revenue recognition was identified as a critical audit matter because it depends on estimates of total expected collaboration-program costs. Revised cost forecasts reduced FY2020 revenue by approximately $6.7 million.
Important facts for investors to verify
- Reconcile the two cash-runway statements and review the assumptions behind the expected funding horizon.
- Track INFRONT-3 enrollment, execution, safety, and clinical outcomes, along with the timing and results of other trial readouts.
- Monitor cash burn, rising R&D costs, and any future equity issuance or other financing needs.
- Review AbbVie option-exercise decisions, collaboration economics, and any contingent milestones; confirm whether Innovent payments or milestones are achieved.
- Check the outcome and final monetary amount of the arbitration proceeding.